Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
Identifieur interne : 001A91 ( Istex/Corpus ); précédent : 001A90; suivant : 001A92Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
Auteurs : Martin J. Hecht ; Henning Stolze ; Matthias Auf Dem Brinke ; Ralf Giess ; Thoams Treig ; Martin Winterholler ; Jörg WisselSource :
- Movement Disorders [ 0885-3185 ] ; 2008-01-30.
English descriptors
Abstract
Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21809
Links to Exploration step
ISTEX:F81B4DBBD9C958C89334DDEEF27F05A7B3CA503FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name><affiliation><mods:affiliation>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, BKH Kaufbeuren, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Kiel, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Diako Hospital, Flensburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Auf Dem Brinke, Matthias" sort="Auf Dem Brinke, Matthias" uniqKey="Auf Dem Brinke M" first="Matthias" last="Auf Dem Brinke">Matthias Auf Dem Brinke</name><affiliation><mods:affiliation>Department of Neurological Rehabilitation, Bad Wildungen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name><affiliation><mods:affiliation>Department of Neurology, Henriettenstiftung, Hannover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name><affiliation><mods:affiliation>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name><affiliation><mods:affiliation>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jörg" last="Wissel">Jörg Wissel</name><affiliation><mods:affiliation>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21809</idno><idno type="url">https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A91</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name><affiliation><mods:affiliation>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, BKH Kaufbeuren, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><affiliation><mods:affiliation>Department of Neurology, University of Kiel, Kiel, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Diako Hospital, Flensburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Auf Dem Brinke, Matthias" sort="Auf Dem Brinke, Matthias" uniqKey="Auf Dem Brinke M" first="Matthias" last="Auf Dem Brinke">Matthias Auf Dem Brinke</name><affiliation><mods:affiliation>Department of Neurological Rehabilitation, Bad Wildungen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name><affiliation><mods:affiliation>Department of Neurology, Henriettenstiftung, Hannover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name><affiliation><mods:affiliation>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name><affiliation><mods:affiliation>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jörg" last="Wissel">Jörg Wissel</name><affiliation><mods:affiliation>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-01-30">2008-01-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="233">233</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</idno><idno type="DOI">10.1002/mds.21809</idno><idno type="ArticleID">MDS21809</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>HSP</term><term>botulinum toxin A</term><term>hereditary spastic paraplegia</term><term>spasticity</term><term>therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Martin J. Hecht MD</name><affiliations><json:string>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</json:string><json:string>Department of Neurology, BKH Kaufbeuren, Germany</json:string></affiliations></json:item><json:item><name>Henning Stolze MD</name><affiliations><json:string>Department of Neurology, University of Kiel, Kiel, Germany</json:string><json:string>Department of Neurology, Diako Hospital, Flensburg, Germany</json:string></affiliations></json:item><json:item><name>Matthias Auf Dem Brinke MD</name><affiliations><json:string>Department of Neurological Rehabilitation, Bad Wildungen, Germany</json:string></affiliations></json:item><json:item><name>Ralf Giess MD</name><affiliations><json:string>Department of Neurology, Henriettenstiftung, Hannover, Germany</json:string></affiliations></json:item><json:item><name>Thoams Treig MD</name><affiliations><json:string>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</json:string><json:string>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</json:string></affiliations></json:item><json:item><name>Martin Winterholler MD</name><affiliations><json:string>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</json:string></affiliations></json:item><json:item><name>Jörg Wissel MD</name><affiliations><json:string>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>hereditary spastic paraplegia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HSP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>botulinum toxin A</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>spasticity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>5.796</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1353</abstractCharCount><pdfWordCount>3384</pdfWordCount><pdfCharCount>21625</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>201</abstractWordCount></qualityIndicators><title>Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><corporate><json:item><name></name></json:item></corporate><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>6</total><last>233</last><first>228</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21809</json:string></doi><id>F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title><author><orgName>German Spasticity Education Group</orgName></author><author><persName><forename type="first">Martin J.</forename><surname>Hecht</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, BKH Kaufbeuren, Am Kaiserweiher 8, D‐87600 Kaufbeuren, Germany</p></note><affiliation>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</affiliation><affiliation>Department of Neurology, BKH Kaufbeuren, Germany</affiliation></author><author><persName><forename type="first">Henning</forename><surname>Stolze</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Kiel, Kiel, Germany</affiliation><affiliation>Department of Neurology, Diako Hospital, Flensburg, Germany</affiliation></author><author><persName><forename type="first">Matthias</forename><surname>Auf Dem Brinke</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurological Rehabilitation, Bad Wildungen, Germany</affiliation></author><author><persName><forename type="first">Ralf</forename><surname>Giess</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Henriettenstiftung, Hannover, Germany</affiliation></author><author><persName><forename type="first">Thoams</forename><surname>Treig</surname><roleName type="degree">MD</roleName></persName><affiliation>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</affiliation><affiliation>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Winterholler</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</affiliation></author><author><persName><forename type="first">Jörg</forename><surname>Wissel</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-01-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="233">233</biblScope></imprint></monogr><idno type="istex">F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</idno><idno type="DOI">10.1002/mds.21809</idno><idno type="ArticleID">MDS21809</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>hereditary spastic paraplegia</term></item><item><term>HSP</term></item><item><term>botulinum toxin A</term></item><item><term>spasticity</term></item><item><term>therapy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-06-27">Received</change><change when="2007-10-05">Registration</change><change when="2008-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body" wicri:toSee="Element #text; element #text"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"> <header> <publicationMeta level="product"> <publisherInfo> <publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName> <publisherLoc>Hoboken</publisherLoc> </publisherInfo> <doi registered="yes">10.1002/(ISSN)1531-8257</doi> <issn type="print">0885-3185</issn> <issn type="electronic">1531-8257</issn> <idGroup> <id type="product" value="MDS"></id> </idGroup> <titleGroup> <title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title> <title type="short">Mov. Disord.</title> </titleGroup> </publicationMeta> <publicationMeta level="part" position="20"> <doi origin="wiley" registered="yes">10.1002/mds.v23:2</doi> <numberingGroup> <numbering type="journalVolume" number="23">23</numbering> <numbering type="journalIssue">2</numbering> </numberingGroup> <coverDate startDate="2008-01-30">30 January 2008</coverDate> </publicationMeta> <publicationMeta level="unit" type="article" position="110" status="forIssue"> <doi origin="wiley" registered="yes">10.1002/mds.21809</doi> <idGroup> <id type="unit" value="MDS21809"></id> </idGroup> <countGroup> <count type="pageTotal" number="6"></count> </countGroup> <titleGroup> <title type="articleCategory">Research Article</title> <title type="tocHeading1">Research Articles</title> </titleGroup> <copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright> <eventGroup><event type="manuscriptReceived" date="2006-06-27"></event><event type="manuscriptRevised" date="2007-07-21"></event><event type="manuscriptAccepted" date="2007-10-05"></event><event type="firstOnline" date="2007-11-12"></event><event type="publishedOnlineFinalForm" date="2008-01-25"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-11-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup> <numberingGroup> <numbering type="pageFirst">228</numbering> <numbering type="pageLast">233</numbering> </numberingGroup> <correspondenceTo>Department of Neurology, BKH Kaufbeuren, Am Kaiserweiher 8, D‐87600 Kaufbeuren, Germany</correspondenceTo> <linkGroup> <link type="toTypesetVersion" href="file:MDS.MDS21809.pdf"></link> </linkGroup> </publicationMeta> <contentMeta> <countGroup> <count type="figureTotal" number="1"></count> <count type="tableTotal" number="1"></count> <count type="referenceTotal" number="13"></count> <count type="wordTotal" number="4034"></count> </countGroup> <titleGroup> <title type="main" xml:lang="en">Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title> <title type="short" xml:lang="en">Botulinum toxin a in HSP</title> </titleGroup> <creators> <creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"> <personName> <givenNames>Martin J.</givenNames> <familyName>Hecht</familyName> <degrees>MD</degrees> </personName> <contactDetails> <email normalForm="martin.hecht@bkh-kaufbeuren.de">martin.hecht@bkh‐kaufbeuren.de</email> </contactDetails> </creator> <creator xml:id="au2" creatorRole="author" affiliationRef="#af3 #af4"> <personName> <givenNames>Henning</givenNames> <familyName>Stolze</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au3" creatorRole="author" affiliationRef="#af5"> <personName> <givenNames>Matthias</givenNames> <familyName>Auf Dem Brinke</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au4" creatorRole="author" affiliationRef="#af6"> <personName> <givenNames>Ralf</givenNames> <familyName>Giess</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au5" creatorRole="author" affiliationRef="#af7 #af8"> <personName> <givenNames>Thoams</givenNames> <familyName>Treig</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au6" creatorRole="author" affiliationRef="#af9"> <personName> <givenNames>Martin</givenNames> <familyName>Winterholler</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au7" creatorRole="author" affiliationRef="#af10"> <personName> <givenNames>Jörg</givenNames> <familyName>Wissel</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au8" creatorRole="author"> <groupName>German Spasticity Education Group</groupName> </creator> </creators> <affiliationGroup> <affiliation xml:id="af1" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af2" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, BKH Kaufbeuren, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af3" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, University of Kiel, Kiel, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af4" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, Diako Hospital, Flensburg, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af5" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurological Rehabilitation, Bad Wildungen, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af6" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, Henriettenstiftung, Hannover, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af7" countryCode="DE" type="organization"> <unparsedAffiliation>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af8" countryCode="DE" type="organization"> <unparsedAffiliation>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af9" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</unparsedAffiliation> </affiliation> <affiliation xml:id="af10" countryCode="DE" type="organization"> <unparsedAffiliation>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</unparsedAffiliation> </affiliation> </affiliationGroup> <keywordGroup xml:lang="en" type="author"> <keyword xml:id="kwd1">hereditary spastic paraplegia</keyword> <keyword xml:id="kwd2">HSP</keyword> <keyword xml:id="kwd3">botulinum toxin A</keyword> <keyword xml:id="kwd4">spasticity</keyword> <keyword xml:id="kwd5">therapy</keyword> </keywordGroup> <abstractGroup> <abstract type="main" xml:lang="en"> <title type="main">Abstract</title> <p>Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</p> </abstract> </abstractGroup> </contentMeta> </header> </component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Botulinum toxin a in HSP</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases</title></titleInfo><name type="personal"><namePart type="given">Martin J.</namePart><namePart type="family">Hecht</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, Germany</affiliation><affiliation>Department of Neurology, BKH Kaufbeuren, Germany</affiliation><description>Correspondence: Department of Neurology, BKH Kaufbeuren, Am Kaiserweiher 8, D‐87600 Kaufbeuren, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Henning</namePart><namePart type="family">Stolze</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Kiel, Kiel, Germany</affiliation><affiliation>Department of Neurology, Diako Hospital, Flensburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Matthias</namePart><namePart type="family">Auf Dem Brinke</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Rehabilitation, Bad Wildungen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ralf</namePart><namePart type="family">Giess</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Henriettenstiftung, Hannover, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thoams</namePart><namePart type="family">Treig</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, Germany</affiliation><affiliation>Neurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Winterholler</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Rummelsberger Kliniken, Schwarzenbruck, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jörg</namePart><namePart type="family">Wissel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>German Spasticity Education Group</namePart><description>Department of Neurology, University of Erlangen‐Nuremberg, Erlangen, GermanyDepartment of Neurology, BKH Kaufbeuren, GermanyDepartment of Neurology, University of Kiel, Kiel, GermanyDepartment of Neurology, Diako Hospital, Flensburg, GermanyDepartment of Neurological Rehabilitation, Bad Wildungen, GermanyDepartment of Neurology, Henriettenstiftung, Hannover, GermanyNeurological Rehabilitation Centre, Ernst‐Moritz‐Arndt University, Greifswald, GermanyNeurological Rehabilitation Centre, Schwarzwaldkliniken, Bad Krozingen, GermanyDepartment of Neurology, Rummelsberger Kliniken, Schwarzenbruck, GermanyDepartment of Neurological Rehabilitation, Beelitz Heilstätten, Beelitz, Germany</description></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-01-30</dateIssued><dateCaptured encoding="w3cdtf">2006-06-27</dateCaptured><dateValid encoding="w3cdtf">2007-10-05</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">13</extent><extent unit="words">4034</extent></physicalDescription><abstract lang="en">Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>hereditary spastic paraplegia</topic><topic>HSP</topic><topic>botulinum toxin A</topic><topic>spasticity</topic><topic>therapy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>228</start><end>233</end><total>6</total></extent></part></relatedItem><identifier type="istex">F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F</identifier><identifier type="DOI">10.1002/mds.21809</identifier><identifier type="ArticleID">MDS21809</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A91 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001A91 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F81B4DBBD9C958C89334DDEEF27F05A7B3CA503F
|texte= Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
}}
| This area was generated with Dilib version V0.6.23. |  |